Claros Technologies
Claros Technologies Raises $55M Series B for PFAS Destruction Technology
Claros Technologies announced $55M in Series B financing on July 28, 2026. Claros Technologies raised a $55 million Series B, inclusive of a prior convertible note financing, led by Treehouse Family Capital to scale manufacturing and commercialize its PFAS destruction system.
Round details
The financing includes backing from Treehouse Family Capital LLC, Daikin America, Inc., Veralto, Bush Foundation, Nord Asset Management, Saint Paul and Minnesota Foundation. The company did not publish a valuation with the announcement.
- Round: Series B
- Capital announced: $55M
- Headquarters: Minneapolis, MN
How the company plans to use the capital
The company said the financing will support expanded manufacturing capacity, additional commercial deployments in North America, Europe, and Asia, and product development. It will also fund growth of the ClarosLabs analytical division, strategic hiring in engineering and commercial operations, and customer support.
Why this matters for GTM teams
The company said the financing will accelerate global commercialization of its ClarosTechUV PFAS Destruction System, including additional commercial deployments across North America, Europe, and Asia.
Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.
Source and methodology
This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.
Primary source: Claros Technologies Series B announcement.
Company Info
Investors (6)
Share
Related Reports
Wabi Raises $55M at $1.25B Valuation in IVP-Led Funding
Wabi announced $55 million in funding led by IVP at a $1.25 billion valuation, which it said will support continued product development and expansion.
StimCardio Raises $30M Series A for Wearable AF Therapeutic
StimCardio announced the closing of an oversubscribed $30 million Series A led by Metis Medtech, expected to fund the company through its planned NeuroPulse 2 pivotal study and preparation for an FDA De Novo submission.
Casap Raises $56M Series B for AI Agents in Financial Services
Casap raised a $56 million Series B led by Base10 Partners, with Experian and Synchrony participating, to advance its AI agent platform for financial services.
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started